CSPC Pharmaceutical Group (HKG:1093) expects a 16% year-over-year decrease in profit attributable to owners for the nine months ended Sept. 30 from 4.49 billion yuan a year earlier, according to a Thursday filing with the Hong Kong bourse.
The company attributed this to lower revenue, which in turn was due to the implementation of volume-based procurement by hospitals, impacting sales in key therapeutic areas such as oncology, cardiovascular, and nervous systems.
The company plans to publish its quarterly results on or about Nov. 15.
The pharmaceutical company's shares were down over 8% in the recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。